Next Article in Journal
Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
Next Article in Special Issue
Lost in Translation: Ambiguity in Nerve Sheath Tumor Nomenclature and Its Resultant Treatment Effect
Previous Article in Journal / Special Issue
Ex Vivo Behaviour of Human Bone Tumor Endothelial Cells
Cancers 2013, 5(2), 418-429; doi:10.3390/cancers5020418

A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma

1,* , 2, 1, 3, 4, 5, 6 and 7
Received: 16 February 2013 / Revised: 25 March 2013 / Accepted: 6 April 2013 / Published: 11 April 2013
(This article belongs to the Special Issue Soft Tissue and Bone Sarcoma)
View Full-Text   |   Download PDF [521 KB, uploaded 11 April 2013]   |   Browse Figure


mTOR inhibitors are emerging as important anti-neoplastic agents with a wide range of clinical applications. The topoisomerase I inhibitor irinotecan is a potent DNA damaging drug, with a broad spectrum of anticancer activities. mTOR appears to enhance cancer cell survival following DNA damage, thus the inhibition of mTOR after irinotecan could theoretically show synergistic activities in patients. Both mTOR inhibitors and irinotecan have been used as single agents in soft tissue sarcomas with limited efficacy. We completed a phase I trial of the combination of the mTOR inhibitor, temsirolimus, and irinotecan in patients with advanced soft tissue sarcoma. Seventeen patients were recruited. The Phase II recommended dose is 20 mg of temsirolimus and 80 mg/m2 of irinotecan administered on weekly basis for three out of four weeks. Most frequently encountered toxicities include cytopenias, fatigue, and gastrointestinal toxicities. Two patients (one with leiomyosarcoma and one with high grade undifferentiated sarcoma) had stable disease for more than 12 months.
Keywords: sarcoma; mTOR inhibitors; irinotecan; temsirolimus; phase I sarcoma; mTOR inhibitors; irinotecan; temsirolimus; phase I
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Verschraegen, C.F.; Movva, S.; Ji, Y.; Schmit, B.; Quinn, R.H.; Liem, B.; Bocklage, T.; Shaheen, M. A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma. Cancers 2013, 5, 418-429.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert